Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi

Citi says Hikma Pharmaceuticals and Fresenius Medical Care could be relative winners if Trump’s proposed tariffs on generic drugs proceed, citing their extensive US manufacturing. The plan calls for a 100% tariff on imported generic medicines from August 2028, rising to 200% a year later, which could disadvantage offshore competitors and support pricing economics for US-linked producers.

Analysis

This is more of a long-dated industrial-policy signal than an immediate earnings event. The economic value accrues to companies that already have US-anchored manufacturing and regulatory-ready capacity, because tariffs that begin in 2028 give customers time to re-source before the policy bites. That makes the real winner the firm with spare domestic throughput and a clean FDA/compliance record, not the one that can best market “reshoring” today.

The first-order loser is the low-margin generic stack with the least flexibility to pass through costs. In a tariff regime this steep, the most fragile products are the commoditized SKUs where a few points of margin disappear quickly; that raises the odds of product exits, shortages, and eventual exemptions. Second-order, that can actually strengthen pricing power for the surviving domestic players and for wholesalers/payers that can lock multi-year supply now, but only after a messy transition period.

Near term, I’d expect the market to over-discount the headline and under-discount the implementation risk. The consensus seems to assume a clean protectionist windfall; the more likely path is lobbying, carve-outs, and delayed enforcement, which makes the policy less about immediate EPS and more about option value on capacity. If the administration softens the tariff or broadens exemptions, the move reverses quickly; if not, the setup becomes a 12-24 month re-rating trade in domestic capacity names.

The contrarian point is that the headline may be leverage, not law: tariffs this punitive can shrink supply enough to force political backtracking. That means the best trade is probably relative value, not outright beta, until we see procurement behavior and concrete plant qualification data.

Key Decisions for Investors

• Prefer a relative-value long HKMPF / FMS versus short an import-heavy generic basket (TEVA, VTRS) for 6-12 months; target 10-15% spread capture, stop if peers announce credible US capacity additions or the tariff framework is diluted.
• Do not chase the headline in the first 1-3 sessions; wait for any post-news pullback in FMS/HKMPF to build a position, since the policy date is too far out for immediate EPS upside to be fully priced.
• If options liquidity is usable, buy 2026-2027 call spreads on FMS or HKMPF only on low implied vol; the trade is time value on policy optionality, not a near-term catalyst.
• Set a hard watch item on exemptions, FDA plant approvals, and import volume data; if carve-outs expand or implementation slips beyond 2028, close the domestic-manufacturing thesis.